Prostate cancer is the most common cancer among men in Europe with approximately 190 000 new cases each year. Approximately 60% of all prostate cancer cases are diagnosed in men over 65 years. The introduction of screening for prostate specific antigen (PSA) levels, and improved diagnostic techniques, however, are diagnosed prostate cancer in younger men, and in the earlier stages of the disease (local tumor in the prostate gland). PSA screening with it an important change since it is now identified numerous tumors with less volume of the prostate gland This means that patients now often live with the disease for many years after diagnosis. In the United States lives of a million men with prostate cancer. It is estimated about 40% of all men between 40 and 49 have prostate cancer. The number is increasing almost exponentially for the next 70% of men between 60 and 69 years. After 70-years of age, approximately 80% of all men prostate cancer.
- Patent Overview